Published in J Clin Invest on July 13, 2015
Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Cell (2016) 1.02
Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines (2016) 0.82
Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat Commun (2017) 0.81
Ebola virus vaccines - reality or fiction? Expert Rev Vaccines (2016) 0.79
Aerosol Delivery of a Candidate Universal Influenza Vaccine Reduces Viral Load in Pigs Challenged with Pandemic H1N1 Virus. J Immunol (2016) 0.78
The Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated Immune Responses. PLoS Pathog (2016) 0.76
Distinct immune responses and virus shedding in pigs following aerosol, intra-nasal and contact infection with pandemic swine influenza A virus, A(H1N1)09. Vet Res (2016) 0.76
BoHV-4-based vector delivering Ebola virus surface glycoprotein. J Transl Med (2016) 0.75
Creation of a protective pulmonary bioshield against inhaled organophosphates using an aerosolized bioscavenger. Ann N Y Acad Sci (2016) 0.75
Ebola: Working Toward Treatments and Vaccines. P T (2015) 0.75
Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys. J Virol (2017) 0.75
Ebola and Marburg virus vaccines. Virus Genes (2017) 0.75
Ebola Virus Binding to Tim-1 on T Lymphocytes Induces a Cytokine Storm. MBio (2017) 0.75
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81
T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol (2008) 11.65
Phenotypic and functional features of human Th17 cells. J Exp Med (2007) 11.33
Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med (2004) 5.22
Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. J Exp Med (2006) 4.91
Selective loss of type I interferon-induced STAT4 activation caused by a minisatellite insertion in mouse Stat2. Nat Immunol (2000) 3.38
IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol (2009) 2.74
Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells. J Exp Med (2004) 2.59
Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol (1995) 2.56
Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet (1996) 2.45
Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology (2005) 2.25
Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med (1996) 2.23
Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J Exp Med (2009) 2.10
Successful topical respiratory tract immunization of primates against Ebola virus. J Virol (2007) 2.06
Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung. J Exp Med (2005) 2.04
Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity (2006) 1.95
Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine (2000) 1.95
Transmission of Ebola viruses: what we know and what we do not know. MBio (2015) 1.90
CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med (2011) 1.83
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A (2013) 1.81
Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection. J Exp Med (2009) 1.72
The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat Immunol (2013) 1.66
The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol (1998) 1.65
Antiviral CD8+ T cell effector activities in situ are regulated by target cell type. J Exp Med (2010) 1.61
A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol (2006) 1.58
Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med (2007) 1.42
CD8⁺ T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung. J Clin Invest (2011) 1.40
T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci U S A (2014) 1.36
Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults. Drugs (2011) 1.33
Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol Rev (2014) 1.28
IL-23 enhances host defense against vaccinia virus infection via a mechanism partly involving IL-17. J Immunol (2007) 1.24
Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology (2008) 1.21
A novel viral system for generating antigen-specific T cells. J Immunol (2005) 1.21
Revealing the role of CD4(+) T cells in viral immunity. J Exp Med (2012) 1.17
Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol (2013) 1.11
Pulmonary vaccine delivery. Expert Rev Vaccines (2007) 1.09
A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology (2008) 1.07
Recent advances in Ebolavirus vaccine development. Hum Vaccin (2010) 1.01
Ebola virus transmission in guinea pigs. J Virol (2014) 1.01
Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc Natl Acad Sci U S A (2008) 0.98
Alpha E beta 7 (CD103) expression identifies a highly active, tonsil-resident effector-memory CTL population. J Immunol (2005) 0.96
Lung deposition of droplet aerosols in monkeys. Inhal Toxicol (2008) 0.93
Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. Clin Vaccine Immunol (2012) 0.87
Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans. Vaccine (2014) 0.78
Ebola haemorrhagic fever. Lancet (2011) 8.28
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med (2002) 3.88
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis (2005) 3.79
Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol (2010) 3.77
Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol (2002) 3.74
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis (2007) 3.51
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. J Biol Chem (2005) 3.08
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2003) 2.82
Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis (2007) 2.68
Genetic diversity between human metapneumovirus subgroups. Virology (2003) 2.65
Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol (2005) 2.65
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis (2007) 2.44
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A (2004) 2.38
A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med (2002) 2.34
Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med (2013) 2.29
Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol (2005) 2.27
Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J Virol (2005) 2.18
Liver disease and cirrhosis because of Khat chewing in UK Somali men: a case series. Liver Int (2010) 2.16
CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol (2009) 2.10
Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett (2002) 2.06
Successful topical respiratory tract immunization of primates against Ebola virus. J Virol (2007) 2.06
Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol (2005) 2.05
Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J Virol (2004) 2.03
The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol (2004) 2.02
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog (2006) 2.01
Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe (2013) 1.97
The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci U S A (2004) 1.85
Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol (2006) 1.85
CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med (2011) 1.83
Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology (2004) 1.81
EPR line shifts and line shape changes due to spin exchange of nitroxide-free radicals in liquids 4. Test of a method to measure re-encounter rates in liquids employing 15N and 14N nitroxide spin probes. J Phys Chem A (2008) 1.81
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A (2013) 1.81
Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci U S A (2011) 1.80
Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol (2005) 1.72
Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A (2004) 1.69
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine (2007) 1.68
Framework for leadership and training of Biosafety Level 4 laboratory workers. Emerg Infect Dis (2008) 1.66
The diagnostic sensitivity of dengue rapid test assays is significantly enhanced by using a combined antigen and antibody testing approach. PLoS Negl Trop Dis (2011) 1.64
A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol (2009) 1.63
Complete genome sequence of avian paramyxovirus type 3 reveals an unusually long trailer region. Virus Res (2008) 1.63
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis (2011) 1.62
FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med (2013) 1.62
Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines (2011) 1.62
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol (2006) 1.58
An optofluidic nanoplasmonic biosensor for direct detection of live viruses from biological media. Nano Lett (2010) 1.57
Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol (2004) 1.55
Nonsegmented negative-strand viruses as vaccine vectors. J Virol (2006) 1.53
Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis (2007) 1.53
Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J Infect Dis (2007) 1.52
Molecular characterization and complete genome sequence of avian paramyxovirus type 4 prototype strain duck/Hong Kong/D3/75. Virol J (2008) 1.50
Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Virol (2003) 1.48
Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis (2011) 1.47
Development of vaccines for Marburg hemorrhagic fever. Expert Rev Vaccines (2007) 1.45
Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology (2002) 1.45
Genetic recombination during coinfection of two mutants of human respiratory syncytial virus. J Virol (2003) 1.44
In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis (2007) 1.43
Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci U S A (2007) 1.39
RhoA signaling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphology. J Virol (2005) 1.36
Complete genome sequence of avian paramyxovirus type 7 (strain Tennessee) and comparison with other paramyxoviruses. Virus Res (2009) 1.36
The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc Natl Acad Sci U S A (2005) 1.36
A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med (2011) 1.35
MassTag polymerase chain reaction for differential diagnosis of viral hemorrhagic fever. Emerg Infect Dis (2006) 1.35
Newcastle disease virus as a vaccine vector for humans. Curr Opin Mol Ther (2008) 1.34
RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother (2007) 1.34
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis (2012) 1.32
Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity. J Virol (2005) 1.32
Complete genome sequence of avian paramyxovirus (APMV) serotype 5 completes the analysis of nine APMV serotypes and reveals the longest APMV genome. PLoS One (2010) 1.31
Complete genome sequence of a novel Newcastle disease virus strain isolated from a chicken in West Africa. J Virol (2012) 1.30
Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J Clin Invest (2002) 1.30
The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis (2006) 1.30
Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol J (2007) 1.30
Complete genome sequences of avian paramyxovirus type 8 strains goose/Delaware/1053/76 and pintail/Wakuya/20/78. Virus Res (2009) 1.30
Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PLoS One (2013) 1.29
Complete genome sequences of avian paramyxovirus serotype 6 prototype strain Hong Kong and a recent novel strain from Italy: evidence for the existence of subgroups within the serotype. Virus Res (2010) 1.29
Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response. PLoS Pathog (2011) 1.28
Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol (2006) 1.28
Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections. J Bioterror Biodef (2011) 1.28
Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis (2012) 1.27